Rottenstein Law Group Alarmed By Research Linking Fosamax and Esophageal Cancer
The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, has learned that researchers have found a link between the drug and cancer of the esophagus.
New York (PRWEB) July 17, 2012
A study recently presented to the 2012 American Society of Clinical Oncology Annual Meeting concludes that the drug alendronate–sold under the brand name Fosamax–is likely linked to cancer of the esophagus. According to the study´s abstract: “In 2009, the US Food and Drug Administration (FDA) reported on 23 patients who had developed distal esophageal cancer, with alendronate“¦ within 2 years of initiation of therapy. Similarly, 31 cases of esophageal cancer were reported from Europe and Japan. Esophagitis has been associated with oral [bisphosphonates]. Erosive esophagitis and persistent mucosal abnormalities have been noted with crystalline material (similar to ground [alendronate]).”
The researchers mined the FDA Adverse Event Reporting System database using terms related to esophageal cancer combined with all drug names for bisphosphonates in instances from 1996 to 2010. The esophageal cancer cases were more common with bisphosphonates than with other drugs in the database. The researchers´ analysis of FDA AERS identified a larger number of cases of esophageal cancer than previously described, and a significant number associated with alendronate use.
Despite being the most popular osteoporosis treatment medication on the market, Fosamax has been linked to several serious side effects. In 2004, researchers found a causal connection between Fosamax and osteonecrosis of the jaw, a condition where the jawbone dies due to a lack of blood supply. More recently, people have suffered low-impact femur fractures after falling from standing height or less. Evidence is building that taking Fosamax or similar medications for the treatment of osteoporosis causes a dramatic increase in risk of this particular kind of rare fracture to the thigh bone.
The Rottenstein Law Group urges anyone whose friend or relative has been prescribed Fosamax or another osteoporosis drug to reach out to that person and recommend that he or she consult a physician immediately and then speak to a qualified personal injury lawyer. The Rottenstein Law Group maintains a Fosamax Lawsuit Information Center at http://www.fosamaxfemurfracturelawsuit.com. The site has features that allow for easy sharing, including links for automatic posting on Facebook and Twitter, specifically to enable visitors to spread the word about the dangers of Fosamax. (Attorney advertising. Prior results do not guarantee a similar outcome.)
About THE ROTTENSTEIN LAW GROUP
The Rottenstein Law Group is a New York-based law firm that represents clients in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients in consumer product injury, mass tort, and class action lawsuits in a compassionate manner. http://www.rotlaw.com
The Rottenstein Law Group, LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
New York, New York 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/7/prweb9699681.htm